AUTL
Autolus Therapeutics plc
stockNASDAQADR
autolus is a private biopharmaceutical company, focused on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. we are building a leading biotechnology company focussed on the development and commercialisation of engineered t-cell therapies for haematological and solid tumours. autolus has the ambition to be a leader of a revolution in medicine in which life-threatening diseases are treated by a patient's own cells.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 1.55 | 2026-10-27 | -9.36% | 3.478 |
| 1M | 1.78 | 2026-10-02 | -21.07% | 2.102 |
| 3M | 1.82 | 2026-08-03 | -22.80% | 1.756 |
| 6M | 1.57 | 2026-05-04 | -10.51% | 1.476 |
| 1Y | 1.56 | 2025-11-03 | -9.94% | 1.835 |
| 2Y | 3.34 | 2024-11-04 | -57.93% | — |
| 5Y | 5.95 | 2021-11-03 | -76.39% | 1.160 |
Autolus Therapeutics plc (NASDAQ:AUTL) stock price today is $1.41, and today's volume is 2,655,317. AUTL is down 1.056% today. The 30 day average volume is 1.84M. AUTL market cap is $373.96M with 266.16M shares outstanding.